Ovarian Cancer

HIPEC Improves Long-Term Outcomes in Stage III Ovarian Cancer

By

Andrea S. Blevins Primeau, PhD, MBA

Publish Date October 2, 2023

Adding HIPEC to interval cytoreductive surgery improves long-term outcomes in stage III epithelial ovarian cancer, a phase 3 trial suggests.

Increased Exposure to PFAS, Phenols Linked to Prior Cancer Diagnosis

Publish Date October 2, 2023

Greater PFDE, PFNA, and PFUA associated with increased odds of previous melanoma.

Immune Checkpoint Inhibitor-Induced LVEF Decreases Rare in Ovarian Cancer

By

Jennifer Larson

Publish Date September 28, 2023

Left ventricular ejection fraction data from the JAVELIN Ovarian 200 trial showed low cardiotoxicity in patients with ovarian cancer treated with avelumab, avelumab plus PLD, or PLD.

Screening Confers “Small” Survival Benefit in High-Grade Serous Ovarian Cancer

By

Leah Lawrence

Publish Date September 15, 2023

Screening can lead to earlier diagnosis of high-grade serous ovarian cancer, but this does not translate to a substantial improvement in survival, according to researchers.

Oncology Nurse Awareness of Targeted Therapy for Ovarian Cancer Limited

By

Vicki Moore, PhD

Publish Date August 21, 2023

A study determined oncology nurses are aware of biomarker testing and targeted therapy for ovarian cancer but seemed less aware of their specific details.

Ovarian Cancer Clinical Trials

Clinical Trial: Specimen and Data Study for Ovarian Cancer Early Detection and Prevention

Clinical Trial: Prophylactic Salpingectomy With Delayed Oophorectomy

Clinical Trial: Interactive Educational Website for Women With Ovarian Cancer & Caregivers

Clinical Trial: Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status

Clinical Trial: AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer